Colorectal Cancer Prevention and Treatment by Inhibition of cyclooxygenase-2

Nat Rev Cancer. 2001 Oct;1(1):11-21. doi: 10.1038/35094017.

Abstract

Population-based studies have established that long-term intake of non-steroidal anti-inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of cyclooxygenase (COX), reduces the relative risk for developing colorectal cancer. These studies led to the identification of a molecular target, COX-2, that is involved in tumour promotion during colorectal cancer progression. Recent studies in humans indicate that therapy with specific COX-2 inhibitors might be an effective approach to colorectal cancer prevention and treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / enzymology
  • Colorectal Neoplasms / prevention & control*
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / therapeutic use*
  • Disease Models, Animal
  • Humans
  • Isoenzymes / antagonists & inhibitors*
  • Isoenzymes / physiology
  • Membrane Proteins
  • Prostaglandin-Endoperoxide Synthases / physiology
  • Prostaglandins / biosynthesis
  • Receptors, Prostaglandin E / physiology

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Membrane Proteins
  • Prostaglandins
  • Receptors, Prostaglandin E
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases